Abilify for bipolar disorder

23 May 2008, 2:49pm

The licence for Abilify (aripiprazole) has been extended to include treatment of moderate to severe manic episodes in bipolar disorder.

It has also been licensed for the prevention of a new manic episode in patients who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.

The recommended starting dose for manic episodes is 15mg once daily. The maximum daily dose should not exceed 30mg.

View Abilify drug record

Further information: BMS/Otsuka

Email this

You must log in to make full use of all the site content and features.

New users can register here free for full site access.

Related Drug Categories

Psychosis

Latest Licence Changes News

MIMS Specialist Journals

Now available on www.mims.co.uk

Click here to view

MIMs Drug Search

Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.

Browse drugs by therapeutic area

MIMS monthly print registration

NICE Guidance: IBS

MIMS Summary of
NICE guideline

NICE Guidance: Lipid Modification

MIMS Summary of
NICE guideline

Quick-reference table: antibiotics

Treatment regimens for common infections

Referral Guidelines for Breast Disorders

MIMS Summary of NHS Cancer Screening Referral Guidelines